Drug manufacturer Amylyx Pharmaceuticals announced on Thursday plans to remove Relyvrio from the market after lackluster results from a phase III trial, leaving only two other ALS drugs on the market.

Some evidence reports natural medications, such as Wugongtang and Dihuangyinzi, may help slow the progression of ALS or Lou Gehrig’s disease. However, they cannot cure it. Amyotrophic lateral ...

The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.

Add Yahoo as a preferred source to see more of our stories on Google. Amyotrophic lateral sclerosis, or ALS, causes nerve cells to degenerate and die, leading to muscle weakness. A landmark study ...

The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient ...

Dr. Rakesh Parekh was in his mid-40s when he first noticed something was wrong: During his workouts, his left arm was weaker and struggled to keep up. Initially, Parekh, an emergency medicine doctor ...

When the results of the first-ever platform trial for amyotrophic lateral sclerosis (ALS) were published this February, the headlines might have seemed disappointing: four experimental drugs failed to ...

Add Yahoo as a preferred source to see more of our stories on Google. A pharmaceutical company based in New Jersey that’s known for its FDA-approved treatment for ALS is set to be acquired for $2.5 ...

One ALS drug made $400 million in sales for its maker. It doesn’t work. A cancer treatment brought in $500 million. That one turned out to have no effect on survival. A blood cancer medication made ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. For over an hour, Jeff Vierstra lay still ...

Unlike other pathologies, amyotrophic lateral sclerosis (ALS) cannot be reproduced accurately in animal models, complicating the development of effective drugs. Faced with this challenge, a group of ...

Interested in finding a better way to develop drugs to treat amyotrophic lateral sclerosis (ALS), Northeastern researcher Jeffrey Agar and a team of scientists came up with a technique that improves ...